BIOVECTRA, a subsidiary of Agilent Technologies Inc., has been recognized with the prestigious 2025 Outsourced Pharma CDMO Leadership Award in the biologics category. This award highlights the company’s outstanding capabilities in quality, reliability, and technical expertise within the biologics sector.
Louis Garguilo, chief editor at Outsourced Pharma, emphasized the significance of the awards, stating, “We are excited to present the 2025 CDMO Leadership Awards winners and provide drug sponsors with a valuable resource for selecting the right partners to bring innovative therapies to market. With new award categories and an improved evaluation system, this year’s selections offer deeper insights into top-performing CDMOs. The official celebration in March will be a key highlight of our event.”
For over 14 years, the CDMO Leadership Awards have been a benchmark for excellence in contract development and manufacturing, recognizing organizations that consistently deliver superior services based on industry feedback and independent research.
Brian Carothers, Vice President and General Manager of the Advanced Manufacturing Partnerships Division at Agilent Technologies, expressed gratitude for the recognition. “This award reflects BIOVECTRA’s unwavering commitment to scientific innovation and client-focused manufacturing solutions. We take great pride in our role in advancing biologics manufacturing and supporting drug sponsors from process development through to commercial production.”
The award winners will be honored at a special ceremony in New York City on March 19, 2025.
BIOVECTRA specializes in cutting-edge biologics, mRNA therapeutics, and complex chemistry, offering end-to-end support in microbial fermentation, protein purification, and single-use bioprocessing. With GMP-certified facilities and aseptic fill-finish capabilities, the company ensures high-quality clinical and commercial-scale manufacturing, helping accelerate drug development while meeting stringent regulatory standards.
